|
|
Aromatase Inhibitors, State of the Science & Strategic OpportunitiesPublished by: AS Insights Published: May. 1, 2003 - 25 Pages Table of ContentsI. Executive Briefing II. State of the Science A. Introduction
2. Chemotherapy 3. Breast Cancer Prevention F. Aromatase Inhibitors Vs Hormone Treatment G. Latest Research Trends III. The Products
2. Femara (Letrozole) 3. Aromasin (Exemestane) 4. Leutaron (Formestane) 5. Afema (Fadrozole) B. Products Launch Sequence C. Dosage & Formulations D. Decision Making & Dispensing Dynamics E. Present Pricing Strategy F. Reimbursement Status G. Products in Clinical Trials
2. YM-511 3. MK0434 4. Finrozole IV. Current Market Situation
2. The US Market 3. European Markets B. Leading Market Participants C. Market Shares
2. Novartis 3. Pfizer V. Future Market Trends AbstractIn recent years, accumulating evidence has demonstrated the utility of aromatase inhibitors as therapy for postmenopausal women with estrogen receptor (ER) positive advanced breast cancer.Aromatase inhibitors have already proved themselves superior, in major clinical trials, to existing hormonal therapies in the fight against breast cancer. These breakthrough findings are likely reinvigorate the market and spur growth rates. Three aromatase inhibitors are currently available in the United States; the nonsteroidal inhibitors anastrozole and letrozole and the steroidal inhibitor exemestane. Another two are available on world markets, formestane and fadozole. Several products are also available in different stages of clinical trials and are expected to enter the market soon By the end of 2002 the world market for aromatase inhibitors was valued at $420 million, a growth of 27% over 2001. The market has been growing at a 24% average annual growth rate over the previous 5 years.
|
|
|||
|
About MarketResearch.com
|
||||